GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
W

Whanin Pharm Co 016580.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

10,740

-0.19%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩255.21bn

FY2016FY2025

Net income

₩13.60bn

FY2016FY2025

Free cash flow

₩2.86bn

FY2016FY2025

Shareholders' equity

₩421.01bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩255.21bn₩259.60bn₩230.39bn₩198.93bn₩177.78bn₩171.71bn₩159.18bn₩154.66bn₩147.95bn₩141.38bn
Gross profit₩87.10bn₩93.78bn₩99.16bn₩98.79bn₩93.49bn₩86.60bn₩79.18bn₩79.30bn₩78.85bn₩69.32bn
Research and development₩1.22bn₩771.1m₩1.07bn₩3.33bn₩2.66bn₩3.31bn₩993.3m₩647.8m₩1.17bn₩827.8m
Operating income₩13.02bn₩21.50bn₩30.17bn₩29.81bn₩31.28bn₩28.42bn₩26.16bn₩27.34bn₩29.65bn₩21.63bn
Net income₩13.60bn₩23.38bn₩29.77bn₩23.92bn₩26.66bn₩23.39bn₩18.70bn₩21.52bn₩27.17bn₩16.40bn
Diluted earnings per share890.491,531.441,950.231,566.861,746.211,531.911,224.591,409.431,779.801,074.04

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩478.89bn₩424.71bn₩401.23bn₩369.37bn₩353.19bn₩329.56bn₩304.88bn₩287.69bn₩274.84bn₩243.44bn
Total liabilities₩57.88bn₩48.70bn₩43.02bn₩35.45bn₩35.96bn₩32.96bn₩30.42bn₩28.10bn₩31.75bn₩23.31bn
Shareholders' equity₩421.01bn₩376.00bn₩358.21bn₩333.51bn₩316.94bn₩296.11bn₩273.78bn₩259.58bn₩243.08bn₩220.13bn
Shares outstanding15m15m15m15m15m15m15m15m15m15m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩9.04bn₩20.69bn₩23.20bn₩16.85bn₩35.32bn₩22.75bn₩24.73bn₩17.45bn₩23.48bn₩19.82bn
Capital spending−₩6.18bn−₩29.38bn−₩31.49bn−₩33.65bn−₩4.39bn−₩7.99bn−₩2.76bn−₩4.10bn−₩19.31bn−₩7.46bn
Free cash flow₩2.86bn−₩8.69bn−₩8.29bn−₩16.80bn₩30.93bn₩14.77bn₩21.97bn₩13.35bn₩4.17bn₩12.36bn
Dividends paid−₩4.58bn−₩4.58bn−₩4.58bn−₩4.58bn−₩4.58bn−₩4.58bn−₩4.58bn−₩4.58bn−₩3.82bn−₩3.82bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩71.42bn₩71.18bn₩65.14bn₩65.74bn₩64.14bn₩60.20bn₩66.25bn₩68.11bn
Gross profit₩27.81bn₩26.27bn₩23.53bn₩21.46bn₩21.19bn₩20.92bn₩21.19bn₩22.99bn
Operating income₩7.89bn₩9.38bn₩1.48bn₩3.56bn₩2.70bn₩5.28bn₩913.1m₩5.29bn
Net income₩7.70bn₩7.47bn₩2.01bn₩3.28bn₩3.19bn₩5.12bn₩3.58bn₩4.52bn
Diluted earnings per share504.29489.02131.77214.56208.80335.37234.77295.82
Cash from operations₩9.26bn₩971.0m₩2.38bn₩5.05bn−₩2.33bn₩3.94bn₩3.64bn₩9.49bn
Capital spending−₩1.01bn−₩623.0m−₩419.0m−₩772.0m−₩3.46bn−₩1.53bn−₩2.84bn−₩3.23bn
Free cash flow₩8.25bn₩348.0m₩1.96bn₩4.28bn−₩5.79bn₩2.41bn₩800.0m₩6.26bn
Total assets₩482.63bn₩481.97bn₩478.89bn₩440.87bn₩429.71bn₩428.93bn₩424.71bn₩422.94bn
Shareholders' equity₩425.47bn₩424.14bn₩421.01bn₩393.81bn₩380.48bn₩375.99bn₩376.00bn₩374.16bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue8.7%8.2%5.8%
Operating income-24.1%-14.5%-6.5%
Net income-17.2%-10.3%-4.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin35.1%40.1%43.2%45.9%
Operating margin6.7%10.0%11.9%13.9%
Net margin7.2%9.6%10.9%12.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings12.77.77.711.210.210.912.613.612.514.8
Price to sales0.70.71.01.41.51.51.51.92.31.7

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 27 Dec 2024.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year300.00300.00300.00300.00300.00300.00300.00300.00
  • 2-for-1 split · 26 Apr 2010
  • 5-for-1 split · 20 Apr 2004
  • 1.02-for-1 split · 2 Jan 2001
  • 21-for-20 split · 4 Jan 2000

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.